Find Clinical Trials

Inclusion Criteria: 1. Inclusion Criteria - Participants with normal weight and normal blood pressure * Have given written informed consent to participate * Aged 18 to 50 years (inclusive) * Females must be post/peri-menopausal or if of child-bearing potential they are required to use adequate contraception and to have a negative pregnancy test (performed at each visit) * Current non-smoker * Body mass index (BMI) in range 18.5-24.9 kg/m2 * Clinic brachial systolic blood pressure \<140 mmHg and diastolic blood pressure \<90 mmHg 2. Inclusion Criteria - Obese participants with normal blood pressure * Have given written informed consent to participate * Aged 18 to 50 years (inclusive) * Male or female * Females must be post/peri-menopausal or if of child-bearing potential they are required to use adequate contraception and to have negative pregnancy test (performed at each visit) * Current non-smoker * BMI ≥30 kg/m2 * Clinic brachial systolic blood pressure \<140 mmHg and diastolic blood pressure \<90 mmHg 3. Inclusion Criteria - Obese participants with high blood pressure * Have given written informed consent to participate * Aged 18 to 50 years (inclusive) * Male or female * Females must be post/peri-menopausal or if of child-bearing potential they are required to use adequate contraception and to have negative pregnancy test (performed at each visit) * Current non-smoker * BMI ≥30 kg/m2 * Diagnosis of stage 1 essential hypertension Exclusion Criteria: * Regular use of medications with vasoactive or cardiac effects in normotensive individuals; inability or unwillingness to omit anti-hypertensive medications on the morning of the study visits in hypertensive individuals * Hypersensitivity to any of the study drugs or excipients * Known clinically significant valvular heart disease * Implanted pacemaker or implantable cardioverter defibrillator (ICD) * Known active malignancy * Known renal impairment (creatinine \>150µmol/L) * Clinically significant neurological disease * History of scleroderma * Current pregnancy, breastfeeding * Current involvement in the active treatment phase of other research studies (excluding observational/non-interventional) * Second or third-degree AV block, sino-atrial block, sick sinus syndrome * Known HIV, hepatitis B or C * Needle phobia * Participants treated with formal anticoagulant therapy such as, but not limited to, heparin or warfarin * Diagnosis of Type 1 or Type 2 Diabetes Mellitus or current usage of insulin or other injectable drugs for the treatment of diabetes such as but not limited to GLP-1 and GIP receptor agonists * BMI \<18.5 kg/m2 * Known heart failure * Currently taking drugs likely to have interactions with semaglutide or tirzepatide * Family history of multiple endocrine neoplasia * Known thyroid cancer * Known history of pancreatitis * History of gall stones (unless the gall bladder has been removed) * Any other clinical reason which may preclude entry in the opinion of the investigator

Inclusion Criteria: * Age ≥18 years * Acute ischemic stroke treated with endovascular therapy (EVT) * Type 2 diabetes mellitus, defined as one of the following: * documented diagnosis of type 2 diabetes mellitus * use of glucose-lowering medication * admission plasma glucose ≥11.1 mmol/L * HbA1c ≥48 mmol/mol (≥6.5%) Exclusion Criteria: * Current pregnancy * Extensive skin infections or dermatological conditions at the intended sensor site * Medical situations known to interfere with CGM accuracy, including: * Hypotension defined as a systolic blood pressure \<100 mmHg at 30 and 60 minutes after admission * Dialysis treatment * Estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m² * Use of medications known to interfere with CGM accuracy, including: * Acetaminophen \>4 g/day * Dopamine * High-dose vitamin C (ascorbic acid) * Hydroxyurea / hydroxycarbamide * Clinically relevant pancreatic disease * Systemic glucocorticoid therapy with a prednisone-equivalent dose \>5 mg/day * Expected admission to an intensive care unit (ICU)

INCLUSION CRITERIA: * Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion * Patients ≥ 18 years of age in ambulatory care * Uncontrolled asthma according to the physician's clinical assessment despite the use of: 1. LABA and high dose ICS or 2. LABA and high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months. * Patients who are eligible for the use of Trimbow 172/5/9 μg pMDI according to the SmPC : 1. at least on exacerbation, requiring systemic (oral or intravenous) corticosteroids in the previous 12 months 2. uncontrolled asthma (ACT≤15) or partially controlled asthma (15\<ACT\<20) 3. FEV1\<80% at baseline * Inhaled asthma therapy was changed to Trimbow 172/5/9 μg pMDI no more than 1 week prior to OR on the day of study inclusion * Patient provided written, informed consent to study participation EXCLUSION CRITERIA: * Participation in any clinical trial within 30 days prior to enrolment * Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment * Another respiratory condition, apart from asthma or COPD, that may interfere with the effectiveness of the treatment studied AND/OR another important clinical situation that may interfere with patient's compliance with the treatment. * Continuous use of oral (\>5 mg prednisolone/day OR \>4 mg methylprednisolone/day) OR intravenous corticosteroids * Use of continuous oxygen therapy * Any malignant disease in the last 5 years * Tuberculosis (active or anamnestic) * Actual or previous use of biologics for asthma treatment in the past 12 months * All exclusion criteria listed in Trimbow 172/5/9 μg pMDI SmPC

Inclusion Criteria: * Age ≥18 years * Hospital admission for first acute myocardial infarction (STEMI or NSTEMI) within 7 days from the index event * PHQ-9 administered at screening * Mini Mental State Examination (MMSE) score ≥26 * Written informed consent obtained Exclusion Criteria: * Previous history of acute myocardial infarction * Diagnosis of major depression according to DSM-5 TR criteria * Severe cognitive impairment (MMSE \<26) * Severe comorbidities with expected survival \<12 months * Inability to participate in scheduled follow-up assessments * Refusal or inability to provide informed consent * Concurrent participation in other interventional clinical studies that could interfere with study outcomes

Inclusion Criteria: * Participants must have been given a diagnosis of a psychiatric disorder (such as mood anxiety, psychotic disorders, etc. * Participants must have reported subjective cognitive difficulties associated with their psychiatric disorder * Participants must be capable of providing informed consent * Participants must have the ability to speak and read in either English or French * Participants must have no changes to their medication intake (such as starting or stopping medication or changing doses) within the past month before providing consent for participation Exclusion Criteria: * Participants will be excluded if they are hospitalized at the time of recruitment * Participants will be excluded if they have a confirmed diagnosis of an intellectual disability

Inclusion Criteria: * Have given written informed consent * Meet DSM-5 criteria for MDD * MADRS \>= 28 at screening Can read, write, and speak English fluently * Be judged by study team clinicians to be at low risk for suicidality Exclusion Criteria: * Women who are pregnant, nursing, or not practicing an effective means of birth control * Cardiovascular conditions: hypertension with resting blood pressure systolic \>139 or diastolic \>89, angina, heart rate \> 99, a clinically significant ECG abnormality (e.g., atrial fibrillation, QTc \> 450), TIA in the last 6 months stroke, peripheral or pulmonary vascular disease, cardiac valvulopathy * Epilepsy * Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia * Currently taking antipsychotics, or MAO inhibitors * Patients taking antidepressant medications and unable to taper * Moderate or strong CYP2D6 inhibitor antidepressants must undergo a washout period of 4 weeks or five half-lives prior to treatment * Currently taking CYP2D6 inhibitor other than an antidepressant that will be tapered * Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or UGT1A9 inhibitors or UGT1A10 inhibitors such as phenytoin, regorafenib, eltrombopag * Have a seizure disorder, multiple sclerosis, history of significant head trauma, CNS tumor, movement disorders or any neurodegenerative condition * Morbidly obese (\>100 lbs. above ideal body weight, or BMI \>=40, or BMI \>=35 with high blood pressure or diabetes) * Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal * Body weight \< 45 kg * Significant acute adverse reaction (e.g., dystonia) to an antipsychotic * Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (including substance-induced), Bipolar I or II Disorder or Major * Depression with psychotic features * Have a first degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or Bipolar I Disorder.

Inclusion Criteria: i) Veterans or first responders ii) 18 -70 years of age iii) Meets criteria for TRD (current major depressive episode without psychotic features by the Mini-International Neuropsychiatric Interview - MINI, with failure to respond to 2 or more evidence-based anti-depressants in the current episode), iv) Meets moderate to severe use criteria for one primary substance (alcohol, cocaine, opioids/heroin, or cannabis). Moderate to severe co-use of nicotine also acceptable, as well as mild/recreational use of other substances, v) Able to read English and complete study evaluations and consent vi) In good health as verified by screening examination and medical history vii) able to safely receive MRI Exclusion Criteria: i) Exclusionary psychiatric conditions include schizophrenia, schizoaffective disorder, bipolar disorder, current post-traumatic stress disorder, or history of medically serious suicide attempt ii) Actively/imminently suicidal (QIDS-SR question 12 score \>2, Hamilton - depression scale (HAM-D) question 3 score \>3, or Montgomery-Åsberg Depression Rating Scale (MADRS) question 10 \>4) ii) A family history of schizophrenia or schizoaffective disorder (first- or second-degree relatives), or bipolar disorder type 1 (first degree relatives) iii) Use of selective serotonin reuptake inhibitors (SSRIs) and other medications are acceptable if dose has remained stable for 6 months, and is not contra-indicated with psilocybin, as per the study physician, Dr Conroy iii) Individuals with any prior use of classic psychedelics, including psilocybin iv) Medical conditions that would preclude safe participation in the trial (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, heart failure, history of cerebrovascular accident, severe asthma, hyperthyroidism, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction) v) Sitting blood pressure below 90/50 mmHG or above 165/95 mmHg vi) EKG evidence of any clinically significant conduction abnormalities, including a Bazett's corrected QT interval (QTc) of \>450 msec for men and QTc\>470 msec for women vii) Women who are pregnant or lactating

Inclusion Criteria: 1. Age range from 18 to 65 years old (including boundary values), both male and female; 2. Single or recurrent episodes that meet the diagnostic criteria for depression in DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition);For patients with a single episode, the duration of this depressive episode must be ≥90 days. 3. Screening and baseline periods, the total score of the Montgomery Asperger Depression Rating Scale (MADRS) was ≥ 26 points; 4. Screening and baseline periods, with a Clinical Global Impression Scale Disease Severity (CGI-S) score of ≥ 4 points; 5. Voluntary participation in clinical trials, able to sign informed consent forms, and able to understand and comply with research procedures. Exclusion Criteria: 1. Individuals with a history of severe drug allergies or allergies to Piper Piper (pepper plant) ; 2. Those who have used at least two antidepressants in sufficient dosage and duration (treated according to the maximum dosage in the instructions for at least 4 weeks) in a single or current episode in the past but still have no effect; 3. The patients of depression secondary to other mental or physical illnesses; 4. Patients of depression with accompanying psychiatric symptoms; 5. Significant suicidal attempt or behavior within the past year, with a score of ≥ 3 on the 10th item (suicidal ideation) of the MADRS scale; 6. Individuals with a history of epileptic seizures (excluding convulsions caused by febrile seizures in children); 7. Individuals who have received depression related systemic physical therapy within 3 months prior to their first administration: modified electroconvulsive therapy (MECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), phototherapy, or systemic psychotherapy; 8. Systematically receiving antidepressant treatment within the first 2 weeks of randomization, or discontinuing antidepressant medication for less than 5 half-lives before randomization; 9. Those with severe unstable cardiovascular and cerebrovascular diseases, respiratory system diseases, gastrointestinal diseases, liver diseases, kidney diseases, blood diseases, endocrine diseases, or a history of such physical diseases; 10. Accompanied by a history of malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ); 11. Screening or baseline electrocardiogram abnormalities that have clinical significance and are deemed unsuitable for inclusion by investigators, such as male QTcF ≥ 450 ms, female QTcF ≥ 470 ms, or having a history of long QT syndrome; 12. During the baseline period, those with a reduction rate of ≥ 25% in the MADRS scale score compared to the screening period; 13. A history of symptomatic orthostatic hypotension (i.e. orthostatic syncope) with clinical significance; 14. During the screening or baseline period, TBIL is above 2 times the upper limit of normal value, and ALT or AST is above 2 times the upper limit of normal value; Cr is higher than 1.2 times the upper limit of normal value; 15. Thyroid dysfunction (TSH above 1.2 times the upper limit of normal value or below 0.8 times the lower limit of normal value) or the presence of hyperthyroidism or hypothyroidism determined by the investigators; Individuals with a history of elevated intraocular pressure or narrow angle glaucoma; 16. Screening period, drug abuse screening positive individuals; 17. A history of alcohol dependence within one year prior to screening(Drinking alcohol for more than 5 years, equivalent ethanol intake, daily alcohol consumption: men \>40 g/d, women \>20 g/d; drinking ≤5 years, equivalent ethanol intake, history of heavy drinking (\>80 g/d) within 2 weeks); 18. Pregnant and lactating women, male or female subjects who have a family planning or are unable to take effective contraceptive measures within 30 days after signing the informed consent form and ending the trial; 19. Screening for individuals who have participated in clinical trials and taken investigational drugs within the first 30 days; 20. The investigators believe that the subjects have poor compliance or there are other clinical, social, or family factors that are not suitable for enrollment.

Inclusion Criteria: * Age 65-85 years; * Presence of depressive symptoms, defined as a score ≥ 5 on the Geriatric Depression Scale-15 items (GDS-15) or ≥ 5 on the Patient Health Questionnaire-9 (PHQ-9). Exclusion Criteria: * Diagnosis of dementia; * Use of antibiotics or anti-inflammatory medications within the previous 8 weeks; * Active gastrointestinal disease; * Severe chronic medical conditions (e.g., advanced-stage cancer, severe cardiac or renal disorders, or other debilitating diseases); * Renal dysfunction; * Current alcohol or substance abuse; * Major surgical procedures within the previous 6 months.

Inclusion Criteria: * Definitive diagnosis of type II diabetes mellitus (HgA1c ≥ 6.5) or pre-diabetes (HgA1c 5.7-6.4) * objective documentation of peripheral neuropathy on EMG/NCS testing defined as a sural-to-radial amplitude ratio of 0.21 or less * presence of painful neuropathy in addition to decreased sensation * with pain rated ≥4/10 on a 0-10 numerical rating scale (NRS) * age 18 years or older * ability to provide informed consent * ability to attend follow-up visits. Exclusion Criteria: * Potential causes of neuropathy other than type II diabetes mellitus (as listed below) * type I diabetes * vitamin B12 deficiency * folate deficiency * thyroid dysfunction, * other nutritional deficiencies * autoimmune disorders * inflammatory disorders * HIV/AIDS * exposure to metals or toxins * multiple myeloma, * moderate to severe lumbar stenosis with neurogenic claudication

Inclusion Criteria: * Men and women * Diagnosis of type 2 diabetes mellitus * Age between 18 and 60 years * Glycated hemoglobin (HbA1c) ≤ 8% * Participant's ability to attend medical appointments, answer questionnaires, and undergo laboratory tests. * Participant's ability to wear a Freestyle® device. * Participant's acceptance and signature of informed consent. * Acceptance of the intervention (consumption of 30 ml of apple cider vinegar) and avoidance of vinegar-based dressings for the entire duration of the intervention. * Consent to participate in the study. Exclusion Criteria: * Other types of diabetes * Chronic kidney disease (eGFR \< 60 ml/min) * Allergy to apple cider vinegar * Use of systemic steroids at supraphysiological doses * Gastroesophageal reflux disease * Peptic ulcer disease * Documented gastroparesis * Pregnancy or lactation * Use of rapid-acting prandial insulin or analogs

Inclusion Criteria: Scoring 4 or above on the First-Level Beck Depression Inventory Patients who regularly receive hemodialysis treatment Individuals who are cognitively capable of understanding the exercise instructions Individuals who voluntarily agree to participate in the study and provide informed consent Exclusion Criteria: Individuals diagnosed with a psychiatric disorder (e.g., major depression, bipolar disorder, schizophrenia, etc.) Individuals who are physically unable to perform relaxation exercises due to musculoskeletal disorders Individuals who have previously participated regularly in relaxation therapy, yoga, meditation, or similar practices Individuals who cannot follow instructions due to hearing, visual, or cognitive impairments Individuals who are simultaneously participating in another psychosocial or physical intervention program \-

Inclusion Criteria * Patients diagnosed with advanced stage of breast cancer; based on pathological analysis (this Data from electronic medical record system). * Undergoing treatment in the selected Hospital * Age group \>18 years of age (Adult) * Hospitalized patient at the selected study setting * Available at the time of data collection; the minimum expected admission time should be no less than 5 days, as the intervention is planned to last for 5 days. * Able to sign the consent form. * Willing to comply with study procedures and instructions. * has cancer pain. Exclusion Criteria * Individuals who are experiencing difficulties in their ability to hear or have a complete loss of hearing. * Individuals who suffer from extreme visual impairment or complete loss of vision. * Not willing to participate in the study. * Patient with Glasgow coma scale \< 15 * Individuals who experience persistent and uncontrollable feelings of nausea, vomiting, or dizziness, individuals with a background of motion sickness (Rational for exclusion: According to previous studies, the utilization of VR intervention may have adverse effects, including Dizziness, nausea, vomiting, and motion sickness (Simón-Vicente et al., 2022).As a result, in order to prevent the exacerbation of these symptoms among patients, they will not be included in the VR intervention) * Individuals with a history of seizures or epilepsy (Rational for exclusion: Individuals diagnosed with epilepsy have frequently been excluded from the participation in virtual reality (VR) research due to the concern that engaging with VR technology could potentially induce seizures in those who have photosensitive epilepsy (Gray et al., 2023) * A patient who has an injury at their eyes, face, or neck that hinders their ability to comfortably utilize virtual reality (VR) hardware or software or poses a safety risk when using the hardware (such as having open sores, wounds, or a skin rash on their face).

Inclusion Criteria: * Healthy volunteers aged 18-35 years without known acute or chronic disease, non-smokers, body mass index (BMI) 20-24.9 kg/m², and negative orthostatic test * Participants aged ≥60 years with arterial hypertension followed at the Department of Hypertension * Hypertension group: controlled arterial hypertension, negative orthostatic test, without diabetes mellitus * Hypertension with orthostatic hypotension group: controlled arterial hypertension and positive orthostatic test indicating orthostatic hypotension * Hypertension with orthostatic hypertension group: controlled arterial hypertension and positive orthostatic test indicating a rise in blood pressure during orthostatic testing * Hypertension with diabetes mellitus group: controlled arterial hypertension and diabetes mellitus without previously diagnosed autonomic dysfunction * Ability to provide written informed consent Exclusion Criteria: * Dementia, neurodegenerative disease, or cognitive impairment preventing understanding of study procedures * Known cardiovascular disease including heart failure (NYHA II-IV), myocardial infarction within the previous 6 months, clinically significant arrhythmias, or peripheral arterial occlusive disease * Uncontrolled arterial hypertension * Change in antihypertensive therapy within the previous 4 weeks * Presence of a cardiac pacemaker * Treatment with antiarrhythmic drugs (class I, III, or IV), digoxin, alpha-receptor blockers, or other medications known to significantly affect heart rate variability or autonomic function * Advanced renal failure (eGFR \<30 mL/min/1.73 m²) or advanced liver failure * Active malignancy * Body mass index ≥35 kg/m² * Acute illness within the previous 4 weeks * Current smoking * Inability to safely perform exercise testing on a cycle ergometer * Severe psychiatric disorders without stable treatment * Pregnancy or breastfeeding * Participation in another clinical study * Refusal or inability to provide written informed consent

Inclusion Criteria: * Type 2 diabetes (ICD-10 DE11.x) * Age 18-74 years * BMI \< 35 kg/m² * eGFR 30-59 ml/min and UACR \> 30 mg/g * Stable medication for ≥3 months * Ability to read and understand Danish Exclusion Criteria: * Type 1 diabetes or other diabetes types * Current vegan diet * Active cancer * Short bowel syndrome or celiac disease * Use of sodium chloride tablets * No access to digital platform (intervention group only)

Inclusion Criteria: * Policlinico Universitario Agostino Gemelli IRCCS: Subjects with NASH documented by liver biopsy or fibroscan and no evidence of another form of liver disease with a BMI ≥ 30 and ≤40 kg/m2. Age 25-65 years. * Coorte Azienda Ospedaliera Mater Domini: subjects with NASH documented by liver fibroscan aged \>40 years with one or more cardiovascular risk factors,including overweight/obesity, elevated blood pressure, dyslipidemia, and dysglycemia * Azienda Ospedaliero-Universitaria Policlinico Federico II: Subjects with NASH documented by fibroscan and no evidence of another form of liver disease. Age 25-65 years. Exclusion Criteria: * All units: Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous 6 months; Liver cirrhosis; End stage renal failure; Participation in any other concurrent therapeutic clinical trial; Any other life-threatening, non-cardiac disease; Pregnancy; Inability to give informed consent; Substantial alcohol consumption (\>20 g/day for women or \>30 g/day for men); Wilson's disease; Lipodystrophy; Parenteral nutrition; Abetalipoproteinemia; Interfering medications (e.g., amiodarone, methotrexate, tamoxifen, corticosteroids).

Inclusion Criteria: * Age between 18 and 45 years * ASA physical status II-III * Diagnosed with preeclampsia * Scheduled for cesarean delivery under spinal anesthesia with cesarean urgency classified as Lucas category 3-4 * Gestational age ≥28 weeks * Provided written informed consent Exclusion Criteria: * Cesarean urgency classified as Lucas category 1-2 * Gestational age \<28 weeks * ASA physical status ≥ IV * Known renal disease * Cardiac instability or known arrhythmia * Requirement of general anesthesia or sedation * Inability to provide informed consent

Inclusion Criteria: * Female Sex * Age range 48-58 years * In menopausal transition phase (pre-menopause or peri-menopause) * Diagnosis of Type 2 Diabetes Mellitus * Have access to and regularly use a smartphone with internet access Exclusion Criteria: * Male Sex * Currently Pregnant * Prior history of total hysterectomy or bilateral oophorectomy * Prior diagnosis of any of the following: Coronary Vascular Disease (CVD) including coronary heart disease, heart failure, congenital heart disease stroke/transient ischemic attack, valvular heart disease, peripheral vascular disease, aortapathy, atrial fibrillation or flutter, other CVD. \- Untreated serious mental illness (e.g, untreated psychosis).

Inclusion Criteria: 1. Must be between 18-45 years old. 2. Has a BMI of 18-25 kg/m2 stable weight over the previous 6 weeks. 3. Is physically and psychologically healthy (incl. regular menstrual cycles in women, no clinical disorders and/or illnesses). Women will be studied during the follicular phase of their menstrual cycle. Menstrual cycle criteria (using PMID 10941950) 18 to 25 years - Cycle variation ≤9 days 26 to 41 years - Cycle variation ≤7 days 42 to 45 years - Cycle variation ≤9 days 4. No current medical or drug treatment (to include steroids or hormones of any type including contraceptives), as assessed by questionnaire. 5. Has a negative pregnancy test (women), no clinically significant abnormalities in blood and urine, and free of traces of drugs. 6. No history of clinically relevant psychiatric illness. 7. No previous history of drug or alcohol abuse. 8. Not a current smoker. 9. No history of brain injury or of learning disability. 10. No previous adverse reaction to sleep deprivation, jet lag, shift work or any of the drugs to be administered. 11. Not vision or hearing impairment unless corrected back to normal. 12. No endocrine disorder (no abnormal thyroid function tests; no abnormal morning blood cortisol; no primary gonadal disease as indicated by serum LH or FSH concentration \> 10 or \> 15 IU/L, respectively; and no hyperprolactinemia indicated by prolactin \> 25 μg/L). 13. No sleep or circadian disorder. 14. Has good habitual sleep with regular bedtimes (between 6 and 10 hours in duration). 15. Not extreme morning- nor extreme evening-type using Horne-Ostberg Morningness-Eveningness criteria. 16. No travel across time zones within one month of entering the study. 17. No shift work within three months of entering the study. 18. No anemia (hematocrit \<38% in men, \<34% in women). 19. No blood donation within the previous 8 weeks. 20. No concurrent participation in another research study.

Inclusion Criteria: * Spanish or Catalan speakers of both sexes between the ages of 18 and 65. * Patients diagnosed with major depression, based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Specifically, patients will be included who meet the criteria for a major depressive episode with a longitudinal diagnosis of major depressive disorder, single or recurrent episode; or bipolar disorder type 1 or 2. Patients must obtain a moderate or higher score, therefore we establish a lower limit of 15 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) (Alonzo et al., 2019). * Patients receiving or not receiving pharmacological treatment for depression will be included, and this will be recorded as an additional variable. * Have the ability and willingness to commit to the study team for supervision of the intervention sessions and close monitoring of safety. * Demonstrate the acquisition of the ability to properly apply home tDCS independently or with the help of a companion. Exclusion Criteria: * Patients with psychotic, schizoaffective, or personality disorders (both cluster A and B). * Patients with a history of neurological disease, intellectual disability, or cognitive impairment (inability to understand instructions or operate equipment). * Any exclusion criteria established by clinical guidelines on non-invasive brain stimulation (Woods et al., 2016): metal implants or head injuries, any electronic devices such as cochlear implants or cardiac pacemakers. Brain stimulation in the last 6 months. Clinical or family history of epilepsy. * Patients with dermatological problems, such as an allergic skin reaction at the electrode site. * High risk of suicide. Assessed through an interview with a psychiatrist and the use of the Spanish-validated Columbia Suicide Risk Scale (C-SSRS) (Al-Halabí et al., 2016). * Drug or alcohol abuse during the study or in the previous 3 months (except for nicotine). * Changes in pharmacological or non-pharmacological treatment (such as structured psychotherapy) during the study or in the 3 months prior to starting the trial. * Pregnancy.